Pinned Tweet
Some hospitals and clinics are running up the score on 340B markups, generating billions in profits with no requirement that patients benefit.
Patients lose. Hospitals win.
It's time to fix 340B.
ow.ly/fUEq50ZLtv5
With over 8,000 innovative medicines in development, America’s strong IP protections help fuel groundbreaking treatment advances while balancing affordability. Learn more: ow.ly/1NjJ5104HGb
Certain peptides, often referred to as “wellness peptides,” have not been subject to the FDA’s gold-standard review for approval and their safety and effectiveness have not been established in clinical trials.
Get the truth behind the latest health and wellness influencer trend: ow.ly/QR135104HAL
“We’ve got a workforce that’s ambitious, young, diverse.” Greater Houston Partnership President and CEO Steve Kean on why Houston is ready to win more biopharmaceutical research and innovation.
ow.ly/PTYg5104zKc
A GLP-1 saved Stacie’s life. We can’t jeopardize America’s innovation ecosystem that makes breakthroughs like this possible.
Tell Washington: Keep America in the lead.
AmericaCures.com
Why Houston? Cari Gallman of @bmsnews says it’s the perfect ecosystem for turning research into new treatments for patients, and that’s why BMS is investing $2.3B there. Learn more ⬇️
ow.ly/vpz551034N5
☠️𝐁𝐎𝐍𝐄-𝐂𝐇𝐈𝐋𝐋𝐈𝐍𝐆 𝐑𝐄𝐏𝐎𝐑𝐓: Hospitals, clinics and their for-profit partners pocketed $142B in 2025 from 340B medicine markups.
The more big hospital systems exploit the program for profit, the more it increases costs for everyone. See the report: ow.ly/oEBy5102A8r
PBMs control almost 80% of the prescription drug market. That’s scarier than any costume you’ll see today.
👻 Don’t let middlemen haunt your pharmacy bill.
Learn more: ow.ly/FW5z5102zyg
Up to 500 FEWER treatments and cures in the next decade. That’s what’s at stake if MFN pulls billions away from medical research.
Learn more: ow.ly/cIvM5102uAk
Yesterday was a special day for the people behind the science in New Jersey.
Biopharmaceutical researchers participating in PhRMA’s researcher fly-in were recognized on the Assembly floor for their contributions to scientific discovery, medical innovation and public health.
At @axios Live’s Beyond the Breakthrough in Richmond, leaders from government and industry joined Axios to discuss the continuing investments that will keep the area’s biopharma sector growing, from smart policies to workforce development. PhRMA was proud to sponsor the event!
Photo credits: Jen Danson for Axios
More than 1 million Americans now go to work every day to research, manufacture and deliver new medicines.
And it’s a 50-state story. Every state, DC and Puerto Rico is home to biopharma jobs.
That’s what American leadership in medicines looks like.
See what biopharma means for your state: ow.ly/y4FZ5102887
@axios Live’s Beyond the Breakthrough: Building Virginia’s Biopharma Future is almost underway in Richmond and PhRMA is proud to sponsor the conversation.
Tune in live to hear more about what Virginia is getting right >> youtube.com/watch?v=EozGFenk…
PhRMA’s @EA_Carpenter on how critical it is to keep America in the lead ➡️ "We get access to more medicines, and we get access to medicines faster, actually about 3 years faster than people in other parts of the world."
Only 1 in 10 medicines that enter clinical trials ever reach patients.
@bmsnews Cari Gallman on the unglamorous but critical middle of drug development and why it’s worth every step. 🏃♂️➡️
P.S. The next @axios Live Beyond the Breakthrough event will be tomorrow in Richmond, VA! Details to join: ow.ly/xEiX5101SwF
“Wellness peptides” are rising in popularity thanks to social media – but are they safe?
PhRMA Chief Medical Officer, Dr. @mybarra, talks about the lack of safety testing around peptides and the real risks associated with them.
ow.ly/MkU55101LA3
“Imagine if your family was waiting on a miracle treatment.”
Learn how America’s leadership in medical innovation translates to more treatments and hope for families battling rare diseases at AmericaCures.com.
BsUFA advances how biosimilars move through development and FDA review while preserving the agency’s rigorous standards for safety, effectiveness and quality. Learn more: ow.ly/2fAe51011CM
A new video explains how a rebate-based rapid verification model, or rebate model, brings greater transparency to the 340B program without disrupting patient access or imposing undue burdens on legitimate safety net providers. ow.ly/biqM5100YpM
